Skip Navigation LinksHome > November 2013 - Volume 32 - Issue 11 > Population Pharmacokinetic–Pharmacodynamic Target Attainment...
Pediatric Infectious Disease Journal:
doi: 10.1097/INF.0b013e31829b5880
Antimicrobial Reviews

Population Pharmacokinetic–Pharmacodynamic Target Attainment Analysis of Imipenem Plasma and Urine Data in Neonates and Children

Yoshizawa, Kenichi MS*; Ikawa, Kazuro PhD*; Ikeda, Kayo PhD*; Ohge, Hiroki MD, PhD; Morikawa, Norifumi PhD*

Collapse Box


Background: Population pharmacokinetic (PK)–pharmacodynamic target attainment analysis of imipenem was performed to elucidate the PK properties in neonates and children and to rationalize and optimize dosing regimens.

Methods: Population PK models were separately developed in neonates and children by simultaneously fitting plasma and urine data from 60 neonates and 39 children. The newly developed models were then used to estimate the probability of attaining the pharmacodynamic target (40% of the time above the minimum inhibitory concentration) against clinical isolates of common bacteria in pediatric patients.

Results: The data were best described by a 1-compartment model in neonates and a 2-compartment model in children, respectively. Renal clearance in children (0.187 L/h/kg) was double that of neonates (0.0783 L/h/kg), whereas the volume of distribution at steady-state was approximately 1.8-fold larger in neonates (0.466 L/kg) than in children (0.260 L/kg). Age was not a statistically significant covariate in the PK of both groups. Infusions (0.5 h) of 15 mg/kg every 8 h (45 mg/kg/day) and 25 mg/kg every 12 h (50 mg/kg/day) were shown to be sufficient against common bacterial isolates in both patient populations. However, 1.5-h infusions of 25 mg/kg every 8 h (75 mg/kg/day) in neonates and 25 mg/kg every 6 h (100 mg/kg/day) in children were required to be effective against Pseudomonas aeruginosa (minimum inhibitory concentration for 90% of the isolates = 16 μg/mL).

Conclusions: These results explain the changes in imipenem PK properties during the human growth process and provide guidance for tailoring dosing regimens in each pediatric age group.

© 2013 by Lippincott Williams & Wilkins, Inc.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.